CalciMedica Inc
Company Profile
Business description
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.
Contact
505 Coast Boulevard South
Suite 307
La JollaCA92037
USAT: +1 858 952-5500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
15
Stocks News & Analysis
stocks
Insignia Financial: Revised deal still attractive
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,941.50 | 15.30 | 0.17% |
CAC 40 | 7,744.41 | 53.81 | -0.69% |
DAX 40 | 24,041.90 | 265.90 | -1.09% |
Dow JONES (US) | 44,502.44 | 179.37 | 0.40% |
FTSE 100 | 9,023.81 | 10.82 | 0.12% |
HKSE | 25,130.03 | 135.89 | 0.54% |
NASDAQ | 20,892.69 | 81.49 | -0.39% |
Nikkei 225 | 39,774.92 | 44.19 | -0.11% |
NZX 50 Index | 12,830.13 | 3.61 | -0.03% |
S&P 500 | 6,309.62 | 4.02 | 0.06% |
S&P/ASX 200 | 8,677.20 | 9.00 | 0.10% |
SSE Composite Index | 3,581.86 | 22.07 | 0.62% |